FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200258368> ?p ?o ?g. }

• W4200258368 endingPage "811" @default.
• W4200258368 startingPage "782" @default.
• W4200258368 abstract "Brain, a subtle organ of multifarious nature presents plethora of physiological, metabolic and bio-chemical convolutions that impede the delivery of biomolecules and thereby resulting in truncated therapeutic outcome in pathological conditions of central nervous system (CNS). The absolute bottleneck in the therapeutic management of such devastating CNS ailments is the BBB. Another pitfall is the lack of efficient technological platforms (due to high cost and low approval rates) as well as limited clinical trials (due to failures of neuro‑leads in late-stage pipelines) for CNS disorders which has become a literal brain drain with poorest success rates compared to other therapeutic areas, owing to time consuming processes, tremendous convolutions and conceivable adverse effects. With the advent of intranasal delivery (via direct N2B or indirect nose to blood to brain), several novel drug delivery carriers viz. unmodified or surface modified nanoparticle based carriers, lipid based colloidal nanocarriers and drysolid/liquid/semisolid nanoformulations or delivery platforms have been designed as a means to deliver therapeutic agents (small and large molecules, peptides and proteins, genes) to brain, bypassing BBB for disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, schizophrenia and CNS malignancies primarily glioblastomas. Intranasal application offers drug delivery through both direct and indirect pathways for the peripherally administered psychopharmacological agents to CNS. This route could also be exploited for the repurposing of conventional drugs for new therapeutic uses. The limited clinical translation of intranasal formulations has been primarily due to existence of barriers of mucociliary clearance in the nasal cavity, enzyme degradation and low permeability of the nasal epithelium. The present review literature aims to decipher the new paradigms of nano therapeutic systems employed for specific N2B drug delivery of CNS drugs through in silico complexation studies using rationally chosen mucoadhesive polymers (exhibiting unique physicochemical properties of nanocarrier's i.e. surface modification, prolonging retention time in the nasal cavity, improving penetration ability, and promoting brain specific delivery with biorecognitive ligands) via molecular docking simulations. Further, the review intends to delineate the feats and fallacies associated with N2B delivery approaches by understanding the physiological/anatomical considerations via decoding the intranasal drug delivery pathways or critical factors such as rationale and mechanism of excipients, affecting the permeability of CNS drugs through nasal mucosa as well as better efficacy in terms of brain targeting, brain bioavailability and time to reach the brain. Additionally, extensive emphasis has also been laid on the innovative formulations under preclinical investigation along with their assessment by means of in vitro /ex vivo/in vivo N2B models and current characterization techniques predisposing an efficient intranasal delivery of therapeutics. A critical appraisal of novel technologies, intranasal products or medical devices available commercially has also been presented. Finally, it could be warranted that more reminiscent pharmacokinetic/pharmacodynamic relationships or validated computational models are mandated to obtain effective screening of molecular architecture of drug-polymer-mucin complexes for clinical translation of N2B therapeutic systems from bench to bedside." @default.
• W4200258368 created "2021-12-31" @default.
• W4200258368 creator A5006284715 @default.
• W4200258368 creator A5017780727 @default.
• W4200258368 creator A5042992302 @default.
• W4200258368 creator A5073726621 @default.
• W4200258368 creator A5074257591 @default.
• W4200258368 date "2022-01-01" @default.
• W4200258368 modified "2023-10-04" @default.
• W4200258368 title "Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies" @default.
• W4200258368 cites W1178578580 @default.
• W4200258368 cites W123438499 @default.
• W4200258368 cites W1488734028 @default.
• W4200258368 cites W1766445465 @default.
• W4200258368 cites W1795697844 @default.
• W4200258368 cites W1963832082 @default.
• W4200258368 cites W1968235575 @default.
• W4200258368 cites W1972667216 @default.
• W4200258368 cites W1972696524 @default.
• W4200258368 cites W1976025492 @default.
• W4200258368 cites W1977332519 @default.
• W4200258368 cites W1977559821 @default.
• W4200258368 cites W1982413610 @default.
• W4200258368 cites W1982760076 @default.
• W4200258368 cites W1982955268 @default.
• W4200258368 cites W1986507279 @default.
• W4200258368 cites W1988305904 @default.
• W4200258368 cites W1990984843 @default.
• W4200258368 cites W1991260622 @default.
• W4200258368 cites W1992054786 @default.
• W4200258368 cites W1992535564 @default.
• W4200258368 cites W1993908233 @default.
• W4200258368 cites W1996830776 @default.
• W4200258368 cites W1998565963 @default.
• W4200258368 cites W2001525797 @default.
• W4200258368 cites W2001683864 @default.
• W4200258368 cites W2006349109 @default.
• W4200258368 cites W2009798263 @default.
• W4200258368 cites W2010902678 @default.
• W4200258368 cites W2011350835 @default.
• W4200258368 cites W2012014320 @default.
• W4200258368 cites W2014202811 @default.
• W4200258368 cites W2022905205 @default.
• W4200258368 cites W2024363028 @default.
• W4200258368 cites W2025486324 @default.
• W4200258368 cites W2031147341 @default.
• W4200258368 cites W2032554316 @default.
• W4200258368 cites W2033205225 @default.
• W4200258368 cites W2034037638 @default.
• W4200258368 cites W2034588313 @default.
• W4200258368 cites W2035536790 @default.
• W4200258368 cites W2035726141 @default.
• W4200258368 cites W2035838068 @default.
• W4200258368 cites W2038064533 @default.
• W4200258368 cites W2040206301 @default.
• W4200258368 cites W2043338390 @default.
• W4200258368 cites W2044682044 @default.
• W4200258368 cites W2045511561 @default.
• W4200258368 cites W2045670750 @default.
• W4200258368 cites W2051575873 @default.
• W4200258368 cites W2052762207 @default.
• W4200258368 cites W2054349797 @default.
• W4200258368 cites W2055605461 @default.
• W4200258368 cites W2064296617 @default.
• W4200258368 cites W2066747137 @default.
• W4200258368 cites W2067496698 @default.
• W4200258368 cites W2070066725 @default.
• W4200258368 cites W2071062898 @default.
• W4200258368 cites W2071438575 @default.
• W4200258368 cites W2072388319 @default.
• W4200258368 cites W2083492332 @default.
• W4200258368 cites W2083537472 @default.
• W4200258368 cites W2085106089 @default.
• W4200258368 cites W2086190854 @default.
• W4200258368 cites W2090456885 @default.
• W4200258368 cites W2090729959 @default.
• W4200258368 cites W2091250479 @default.
• W4200258368 cites W2091322268 @default.
• W4200258368 cites W2093918270 @default.
• W4200258368 cites W2096642458 @default.
• W4200258368 cites W2097593124 @default.
• W4200258368 cites W2104009433 @default.
• W4200258368 cites W2104347910 @default.
• W4200258368 cites W2113185499 @default.
• W4200258368 cites W2113513792 @default.
• W4200258368 cites W2113945122 @default.
• W4200258368 cites W2114179943 @default.
• W4200258368 cites W2118656007 @default.
• W4200258368 cites W2120079964 @default.
• W4200258368 cites W2122383501 @default.
• W4200258368 cites W2135195095 @default.
• W4200258368 cites W2142178060 @default.
• W4200258368 cites W2147652874 @default.
• W4200258368 cites W2151794502 @default.
• W4200258368 cites W2153002415 @default.
• W4200258368 cites W2153284686 @default.
• W4200258368 cites W2162752807 @default.
• W4200258368 cites W2163607094 @default.

• next